Clarithromycin for treating sepsis in adults.

Area of Science:

• Critical care medicine
• Infectious diseases
• Pharmacology

Background:

• Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection.
• Antibiotic therapy is the cornerstone of sepsis treatment, but optimal antibiotic choice remains an area of active research.
• Clarithromycin, a macrolide antibiotic, has potential antimicrobial properties relevant to sepsis pathogens.

Purpose of the Study:

• To evaluate the benefits and harms of using clarithromycin for treating sepsis in adults.
• To compare clarithromycin monotherapy against standard care (with or without placebo or alternative active intervention).
• To assess clarithromycin in combination with other antibiotics versus standard care in sepsis patients.

Main Methods:

• This study is a protocol for a Cochrane Review of interventions.
• Systematic review methodology will be employed to synthesize evidence.
• Eligibility criteria will focus on randomized controlled trials comparing clarithromycin-based regimens to standard care for sepsis.

Main Results:

• The review aims to identify and synthesize data on clinical outcomes, mortality, and adverse events.
• Specific focus on benefits and harms associated with clarithromycin use in adult sepsis.
• Evidence synthesis will inform clinical practice guidelines for sepsis management.

Conclusions:

• The findings will guide clinicians on the role of clarithromycin in adult sepsis treatment.
• This review will contribute to evidence-based recommendations for antibiotic selection in sepsis.
• Understanding the benefits and harms of clarithromycin is crucial for optimizing sepsis care.